A case of common bile duct cancer that completely responded to combination chemotherapy of gemcitabine and TS-1

Joo Hyun Lim, Ji Kon Ryu, Yoon Jin Choi, Jieun Kwon, Ji Yeon Kim, Yun Bin Lee, Jae Hwan Kim, Won Jae Yoon, Yong Tae Kim, Yong Bum Yoon

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Common bile duct (CBD) cancer is a relatively rare malignancy that arises from the biliary epithelium and is associated with a poor prognosis. Here, we report a case of advanced metastatic CBD cancer successfully treated by chemotherapy with gemcitabine combined with S-1 (tegafur+gimeracil+oteracil). A 65-year-old male presented with pyogenic liver abscess. After antibiotic therapy and percutaneous drainage, follow-up computed tomography (CT) showed an enhanced nodule in the CBD. Biopsy was performed at the CBD via endoscopic retrograde cholangiopancreatography, which showed adenocarcinoma. Additional CT and magnetic resonance imaging showed multiple small nodules in the right hepatic lobe, which were confirmed as metastatic adenocarcinoma by sono-guided liver biopsy. The patient underwent combination chemotherapy with gemcitabine and S-1. After nine courses of chemotherapy, the hepatic lesion disappeared radiologically. Pylorus-preserving pancreaticoduodenectomy was performed, and no residual tumor was found in the resected specimen. Three weeks after the operation, the patient was discharged with no complications. Through 3 months of follow-up, no sign of recurrence was observed on CT scan. Gemcitabine combined with S-1 may be a highly effective treatment for advanced cholangiocarcinoma.

Original languageEnglish
Pages (from-to)371-376
Number of pages6
JournalGut and Liver
Volume7
Issue number3
DOIs
StatePublished - 1 May 2013

Keywords

  • Cholangiocarcinoma
  • Gemcitabine
  • S-1

Cite this